197 filings
Page 8 of 10
6-K
nasgeb
25 Jan 16
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA®(pembrolizumab) for Patients with Hodgkin Lymphoma
12:00am
6-K
vdd8pbg7qi74aq94lcj
21 Jan 16
Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board
12:00am
6-K
vncp4par pn04tti
8 Jan 16
Transforming Immuno - Oncology Using Next - Generation Immune Cell Engagers Corporate Presentation January 2016
12:00am
6-K
4ejr8mptj9
16 Dec 15
Extraordinary General Meeting of Shareholders
12:00am
6-K
xiu85h 99333zkil
7 Dec 15
Affimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH
12:00am
6-K
w3ppmr0ju
10 Nov 15
Index to Condensed Consolidated Financial Statements
12:00am
EFFECT
d799bvh4
23 Oct 15
Notice of effectiveness
12:00am
CORRESP
zgeh xsxiooxrzvnc
22 Oct 15
Correspondence with SEC
12:00am
F-3/A
iuzs8v
15 Oct 15
Shelf registration (foreign) (amended)
12:00am
6-K
vc1nne9s
14 Oct 15
Affimed Announces Significant Investment by an Existing Shareholder
12:00am
UPLOAD
gbfo5oxo4w1thd
8 Oct 15
Letter from SEC
12:00am
F-3
6m9o639
1 Oct 15
Shelf registration (foreign)
12:00am
6-K
1dxzt9lbxqh7
15 Sep 15
Current report (foreign)
12:00am
6-K
svzpj563
4 Aug 15
Current report (foreign)
12:00am
6-K
y33b7005g8q9 u66qh
10 Jun 15
Current report (foreign)
12:00am
6-K
ovbuqbkmes
29 May 15
Current report (foreign)
12:00am
6-K
xotq38g
21 May 15
Index to Condensed Consolidated Financial Statements
12:00am
POS EX
d2lb8kld6z69
12 May 15
Additional exhibits for listing
12:00am
6-K
2kzty0adok
12 May 15
Affimed N.V. Announces Pricing of Public Offering of Common Stock
12:00am
6-K
ji04nzk3jxs9oyi
12 May 15
Affimed N.V. Announces Shareholder Meeting
12:00am